New Initiative To Address Lack Of Paediatric-Specific HIV Treatments 19/05/2014 by Catherine Saez, Intellectual Property Watch Leave a Comment As the World Health Assembly, a new partnership has been launched by three major public health actors in the field of HIV treatment. The initiative is meant to find improved treatments for children suffering from HIV/AIDs. Although all actors agree that significant progress has been made on adult treatments, children-specific medicines are still lacking.
WHO Report Compares Prices, IP Status Of HIV Treatment In Middle-Income Countries 16/05/2014 by Julia Fraser for Intellectual Property Watch Leave a Comment A new report from the World Health Organization concludes that prices of HIV treatments vary greatly between middle-income countries (MICs), often depending on patent landscape, licensing agreements, whether drugs were sourced from originator companies, and regulatory approval. For third-line treatments, the price of drugs remains a challenge for all, with newer products more likely to be patented in key countries of production.
IP, R&D Among Issues In Packed Agenda Of 2014 World Health Assembly 16/05/2014 by William New, Intellectual Property Watch 1 Comment The annual World Health Assembly kicks off next week with a full agenda of new and old public health issues, including several related to intellectual property, pricing, and research and development. Below is a guide to the key issues for Intellectual Property Watch readers.
IP-Watch Subscribers – Updated List Of IP Delegates In Geneva 13/05/2014 by Julia Fraser for Intellectual Property Watch and Maëli Astruc for Intellectual Property Watch Leave a Comment The Geneva IP delegates list is updated! As a special feature for our subscribers, Intellectual Property Watch has assembled a new list of many of the leading government delegates working on intellectual property issues in Geneva.
Special Report – Students To Universities: “We Have A Drug Problem” 13/05/2014 by Julia Fraser for Intellectual Property Watch 6 Comments BASEL — Students from around the world are gathering momentum to challenge their universities’ licensing policies and research and development systems. That was one of the messages emerging from the annual meeting of Universities Allied for Essential Medicines (UAEM) Europe.
Panel: Good Governance Is Key To Achieving Global Health Goals 09/05/2014 by Julia Fraser for Intellectual Property Watch Leave a Comment As the future United Nations development goals are being debated and decided, two important reports make the case for inclusion of a discussion on global governance and its impact on health.
Panel Looks At Ethical Implications Of Big Data In Health 05/05/2014 by Joséphine De Ruyck for Intellectual Property Watch 1 Comment The potential for big data to yield better outcomes in all aspects of health is tremendous, and tapping into it has only just begun, said speakers at a recent panel in Geneva.
UNCTAD Review Of Bangladesh Calls For Drug Market Opening 01/05/2014 by Catherine Saez, Intellectual Property Watch 1 Comment An investment policy review undertaken by the United Nations Conference on Trade and Development (UNCTAD) found that Bangladesh needs to attract foreign direct investment to sustain its development and suggests that the country loosen its grip on the pharmaceutical sector. Bangladesh said the review will be carefully considered.
WTO To Consider Five Australia Plain Packaging Disputes Under One Panel 26/04/2014 by Catherine Saez and William New, Intellectual Property Watch 9 Comments The World Trade Organization Dispute Settlement Body yesterday agreed to establish two more panels in a dispute against Australia’s plain packaging for tobacco products, bringing the total to five. And it was agreed that a single panel will be appointed to study the five complaints.
Special Report: One Year On At The Medicines Patent Pool: Interview With Greg Perry 24/04/2014 by Julia Fraser for Intellectual Property Watch Leave a Comment Greg Perry has been executive director of the Medicines Patent Pool (MPP) for over a year now, since January 2013. Under his guidance, MPP shares that it has launched a “series of new licensing agreements and negotiations with key patent holders and generic medicines companies.” Intellectual Property Watch sat down with Perry recently to discuss why the MPP is so important as an alternative business model, the context of the MPP, changes in the global approach to the issue of access, and how the MPP fits within the Geneva context.